Primary urethral cancer: Treatment patterns, responses and survival in localized, advanced and metastatic patients
Abstract Introduction Primary urethral cancer (PUC) is rare, and limited data exist on optimal treatment and survival, particularly in metastatic cases. The objective of this study was to describe treatment patterns, responses and survival in a contemporary cohort. Patients and Methods Data from pat...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-07-01
|
| Series: | BJUI Compass |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/bco2.70056 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839612668843917312 |
|---|---|
| author | Ilfad Blazevic Aude Fléchon Géraldine Pignot Benoît Mesnard Jérôme Rigaud Mathieu Roumiguié Michel Soulié Constance Thibault Laurence Crouzet Camille Goislard De Monsabert Felix Lefort Marine Gross‐Goupil Luca Campedel Mathieu Laramas Thomas Filleron Elodie Martin Léonor Chaltiel Damien Pouessel |
| author_facet | Ilfad Blazevic Aude Fléchon Géraldine Pignot Benoît Mesnard Jérôme Rigaud Mathieu Roumiguié Michel Soulié Constance Thibault Laurence Crouzet Camille Goislard De Monsabert Felix Lefort Marine Gross‐Goupil Luca Campedel Mathieu Laramas Thomas Filleron Elodie Martin Léonor Chaltiel Damien Pouessel |
| author_sort | Ilfad Blazevic |
| collection | DOAJ |
| description | Abstract Introduction Primary urethral cancer (PUC) is rare, and limited data exist on optimal treatment and survival, particularly in metastatic cases. The objective of this study was to describe treatment patterns, responses and survival in a contemporary cohort. Patients and Methods Data from patients diagnosed with PUC between January 1, 2000 and December 31, 2018, were retrospectively collected from nine French tertiary centres. To enhance the statistical power of survival analysis in the metastatic stage, patients with synchronous and metachronous metastatic disease were pooled. Results We identified 71 patients (62% males, 38% females). The most common histological types were urothelial (40.0%), squamous cell (34.3%) and adenocarcinomas (14.3%). At diagnosis, 35.2% had localized disease, 49.3% had locally advanced disease and 15.5% had distant metastases. Twenty‐seven patients had a metachronous metastatic cancer. Multimodal therapy was used in 24% of localized and 57.1% of locally advanced disease. Among the 60 patients with non‐metastatic disease, median disease‐free survival (DFS) was 21.2 months. Nodal involvement was associated with worse DFS (HR: 2.03, p = 0.039), while multimodal treatment did not improve DFS (HR: 1.22, p = 0.5419). For metastatic patients, median overall survival was 15.2 months, and progression‐free survival was 6.4 months. Main study limitations were an overrepresentation of locally advanced disease and the small cohort size. Conclusions This retrospective study highlights the significant heterogeneity in terms of histology, stage at diagnosis and treatment of PUC. This study is one of the few to describe treatments and survival in metastatic PUC patients. Efforts must be made to improve survival in these patients. |
| format | Article |
| id | doaj-art-a4e02b936e7747e2b920bbecf56aeee9 |
| institution | Matheson Library |
| issn | 2688-4526 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | BJUI Compass |
| spelling | doaj-art-a4e02b936e7747e2b920bbecf56aeee92025-07-28T05:18:38ZengWileyBJUI Compass2688-45262025-07-0167n/an/a10.1002/bco2.70056Primary urethral cancer: Treatment patterns, responses and survival in localized, advanced and metastatic patientsIlfad Blazevic0Aude Fléchon1Géraldine Pignot2Benoît Mesnard3Jérôme Rigaud4Mathieu Roumiguié5Michel Soulié6Constance Thibault7Laurence Crouzet8Camille Goislard De Monsabert9Felix Lefort10Marine Gross‐Goupil11Luca Campedel12Mathieu Laramas13Thomas Filleron14Elodie Martin15Léonor Chaltiel16Damien Pouessel17Oncopole Claudius Regaud Toulouse FranceCentre Léon Bérard Lyon FranceInstitut Paoli‐Calmettes Marseille FranceCentre Hospitalier Universitaire de Nantes Nantes FranceCentre Hospitalier Universitaire de Nantes Nantes FranceCentre Hospitalier Universitaire de Toulouse Toulouse FranceCentre Hospitalier Universitaire de Toulouse Toulouse FranceHôpital Georges Pompidou, AP‐HP. Centre‐Université de Paris Paris FranceCentre Eugène Marquis Rennes FranceCentre Eugène Marquis Rennes FranceHôpital Saint‐André, Centre Hospitalier Universitaire de Bordeaux Bordeaux FranceHôpital Saint‐André, Centre Hospitalier Universitaire de Bordeaux Bordeaux FranceGroupe Hospitalier Pitié‐Salpêtrière Paris FranceCentre Hospitalier Universitaire Grenoble FranceOncopole Claudius Regaud Toulouse FranceOncopole Claudius Regaud Toulouse FranceOncopole Claudius Regaud Toulouse FranceOncopole Claudius Regaud Toulouse FranceAbstract Introduction Primary urethral cancer (PUC) is rare, and limited data exist on optimal treatment and survival, particularly in metastatic cases. The objective of this study was to describe treatment patterns, responses and survival in a contemporary cohort. Patients and Methods Data from patients diagnosed with PUC between January 1, 2000 and December 31, 2018, were retrospectively collected from nine French tertiary centres. To enhance the statistical power of survival analysis in the metastatic stage, patients with synchronous and metachronous metastatic disease were pooled. Results We identified 71 patients (62% males, 38% females). The most common histological types were urothelial (40.0%), squamous cell (34.3%) and adenocarcinomas (14.3%). At diagnosis, 35.2% had localized disease, 49.3% had locally advanced disease and 15.5% had distant metastases. Twenty‐seven patients had a metachronous metastatic cancer. Multimodal therapy was used in 24% of localized and 57.1% of locally advanced disease. Among the 60 patients with non‐metastatic disease, median disease‐free survival (DFS) was 21.2 months. Nodal involvement was associated with worse DFS (HR: 2.03, p = 0.039), while multimodal treatment did not improve DFS (HR: 1.22, p = 0.5419). For metastatic patients, median overall survival was 15.2 months, and progression‐free survival was 6.4 months. Main study limitations were an overrepresentation of locally advanced disease and the small cohort size. Conclusions This retrospective study highlights the significant heterogeneity in terms of histology, stage at diagnosis and treatment of PUC. This study is one of the few to describe treatments and survival in metastatic PUC patients. Efforts must be made to improve survival in these patients.https://doi.org/10.1002/bco2.70056adenocarcinomachemotherapyprimary urethral cancerradiation therapysquamous cell carcinomasurgery |
| spellingShingle | Ilfad Blazevic Aude Fléchon Géraldine Pignot Benoît Mesnard Jérôme Rigaud Mathieu Roumiguié Michel Soulié Constance Thibault Laurence Crouzet Camille Goislard De Monsabert Felix Lefort Marine Gross‐Goupil Luca Campedel Mathieu Laramas Thomas Filleron Elodie Martin Léonor Chaltiel Damien Pouessel Primary urethral cancer: Treatment patterns, responses and survival in localized, advanced and metastatic patients BJUI Compass adenocarcinoma chemotherapy primary urethral cancer radiation therapy squamous cell carcinoma surgery |
| title | Primary urethral cancer: Treatment patterns, responses and survival in localized, advanced and metastatic patients |
| title_full | Primary urethral cancer: Treatment patterns, responses and survival in localized, advanced and metastatic patients |
| title_fullStr | Primary urethral cancer: Treatment patterns, responses and survival in localized, advanced and metastatic patients |
| title_full_unstemmed | Primary urethral cancer: Treatment patterns, responses and survival in localized, advanced and metastatic patients |
| title_short | Primary urethral cancer: Treatment patterns, responses and survival in localized, advanced and metastatic patients |
| title_sort | primary urethral cancer treatment patterns responses and survival in localized advanced and metastatic patients |
| topic | adenocarcinoma chemotherapy primary urethral cancer radiation therapy squamous cell carcinoma surgery |
| url | https://doi.org/10.1002/bco2.70056 |
| work_keys_str_mv | AT ilfadblazevic primaryurethralcancertreatmentpatternsresponsesandsurvivalinlocalizedadvancedandmetastaticpatients AT audeflechon primaryurethralcancertreatmentpatternsresponsesandsurvivalinlocalizedadvancedandmetastaticpatients AT geraldinepignot primaryurethralcancertreatmentpatternsresponsesandsurvivalinlocalizedadvancedandmetastaticpatients AT benoitmesnard primaryurethralcancertreatmentpatternsresponsesandsurvivalinlocalizedadvancedandmetastaticpatients AT jeromerigaud primaryurethralcancertreatmentpatternsresponsesandsurvivalinlocalizedadvancedandmetastaticpatients AT mathieuroumiguie primaryurethralcancertreatmentpatternsresponsesandsurvivalinlocalizedadvancedandmetastaticpatients AT michelsoulie primaryurethralcancertreatmentpatternsresponsesandsurvivalinlocalizedadvancedandmetastaticpatients AT constancethibault primaryurethralcancertreatmentpatternsresponsesandsurvivalinlocalizedadvancedandmetastaticpatients AT laurencecrouzet primaryurethralcancertreatmentpatternsresponsesandsurvivalinlocalizedadvancedandmetastaticpatients AT camillegoislarddemonsabert primaryurethralcancertreatmentpatternsresponsesandsurvivalinlocalizedadvancedandmetastaticpatients AT felixlefort primaryurethralcancertreatmentpatternsresponsesandsurvivalinlocalizedadvancedandmetastaticpatients AT marinegrossgoupil primaryurethralcancertreatmentpatternsresponsesandsurvivalinlocalizedadvancedandmetastaticpatients AT lucacampedel primaryurethralcancertreatmentpatternsresponsesandsurvivalinlocalizedadvancedandmetastaticpatients AT mathieularamas primaryurethralcancertreatmentpatternsresponsesandsurvivalinlocalizedadvancedandmetastaticpatients AT thomasfilleron primaryurethralcancertreatmentpatternsresponsesandsurvivalinlocalizedadvancedandmetastaticpatients AT elodiemartin primaryurethralcancertreatmentpatternsresponsesandsurvivalinlocalizedadvancedandmetastaticpatients AT leonorchaltiel primaryurethralcancertreatmentpatternsresponsesandsurvivalinlocalizedadvancedandmetastaticpatients AT damienpouessel primaryurethralcancertreatmentpatternsresponsesandsurvivalinlocalizedadvancedandmetastaticpatients |